CIK: 0001773195
Total reported value
$1.9B
Reporting period: 2026-03-31 · Number of holdings: 105
Affinity Asset Advisors, LLC disclosed 105 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.9B and a quarterly turnover rate of 77.9%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "A"
Affinity Asset Advisors, LLC's disclosed holdings carry a Herfindahl concentration index of 0.026 — mathematically equivalent to about 38 equally-sized positions, well below its 105 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.30), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 23% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add ERAS
+37.2% $72.1M
Trim WVE
-48.1% -$35.7M
Add 260
+133.1% $40.6M
Add ROIV
+64.7% $40.7M
Add XENE
+34.0% $41.4M
Trim ABVX
-19.8% -$23.0M
Showing top 103 holdings (of 105 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 6.72% | +6.72% | NEW | |
| 2 | APGE | Apogee Therapeutics INC | Stock-Other | 5.59% | +0.28% | +4.05% | |
| 3 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 5.03% | +1.84% | +34.00% | |
| 4 | ERAS | Erasca INC | Stock-Other | 4.47% | +3.64% | +37.18% | |
| 5 | INSM | Insmed INC | Stock-Healthcare | 4.05% | — | +6.67% | |
| 6 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 4.01% | +1.91% | +64.71% | |
| 7 | SYRE | Spyre Therapeutics INC | Stock-Other | 3.33% | +0.66% | -10.71% | |
| 8 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.87% | +2.01% | +133.12% | |
| 9 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.83% | — | -8.11% | |
| 10 | ANAB | Anaptysbio INC | Stock-Other | 2.69% | +1.46% | +111.38% | |
| 11 | ALKS | Alkermes plc | Stock-Healthcare | 2.47% | +0.88% | +35.00% | |
| 12 | CYTK | Cytokinetics INC | Stock-Healthcare | 2.38% | — | -12.44% | |
| 13 | ABVX | Abivax Sa-adr | Stock-Other | 2.33% | -1.55% | -19.80% | |
| 14 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 2.18% | — | — | |
| 15 | ACLXGBX | Arcellx INC | Stock-Other | 2.15% | +0.20% | -30.73% | |
| 16 | MRNA | Moderna INC | Stock-Healthcare | 2.10% | +2.10% | NEW | |
| 17 | DNTH | Dianthus Therapeutics INC | Stock-Other | 1.73% | +1.46% | +247.83% | |
| 18 | NUVL | Nuvalent Inc-a | Stock-Other | 1.59% | — | -7.02% | |
| 19 | 430 | Terns Pharmaceuticals INC | Stock-Other | 1.53% | +0.26% | +2.30% | |
| 20 | LXEO | Lexeo Therapeutics INC | Stock-Other | 1.50% | — | +57.82% | |
| 21 | COGT | Cogent Biosciences INC | Stock-Other | 1.49% | +0.78% | +114.29% | |
| 22 | MDGL | Madrigal Pharmaceuticals INC | Stock-Healthcare | 1.49% | +0.46% | +76.67% | |
| 23 | STRO | Sutro Biopharma INC | Stock-Other | 1.38% | +0.89% | +42.91% | |
| 24 | FBRX | Forte Biosciences INC | Stock-Other | 1.35% | — | — | |
| 25 | ORKA | Oruka Therapeutics INC | Stock-Other | 1.27% | — | -37.72% | |
| 26 | TRVI | Trevi Therapeutics INC | Stock-Other | 1.23% | — | -6.98% | |
| 27 | OVID | Ovid Therapeutics INC | Stock-Other | 1.22% | +0.56% | +48.76% | |
| 28 | ELVN | Enliven Therapeutics INC | Stock-Other | 1.19% | +1.19% | NEW | |
| 29 | ASND | Ascendis Pharma A/S | Stock-Other | 1.12% | +0.76% | +216.67% | |
| 30 | MLYS | Mineralys Therapeutics INC | Stock-Other | 1.05% | — | +2.74% | |
| 31 | AVTX | Avalo Therapeutics INC | Stock-Other | 1.03% | — | +27.57% | |
| 32 | RVMD | Revolution Medicines INC | Stock-Healthcare | 1.00% | +0.55% | +100.00% | |
| 33 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 0.94% | +0.94% | NEW | |
| 34 | PTGX | Protagonist Therapeutics INC | Stock-Other | 0.94% | — | — | |
| 35 | CLDX | Celldex Therapeutics INC | Stock-Other | 0.82% | — | +42.86% | |
| 36 | ✓ | Zura Bio LTD | Stock-Other | 0.79% | — | +41.39% | |
| 37 | NRIX | Nurix Therapeutics INC | Stock-Other | 0.77% | — | — | |
| 38 | SVRA | Savara INC | Stock-Other | 0.71% | — | -10.19% | |
| 39 | OMER 9.5 06-15-29 | Omeros CORP | Stock-Other | 0.68% | — | — | |
| 40 | CATX | Perspective Therapeutics INC | Stock-Other | 0.68% | +0.63% | +954.86% | |
| 41 | ✓ | Helix Acquisition CORP Iii | Stock-Other | 0.66% | +0.66% | NEW | |
| 42 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.65% | +0.39% | +185.71% | |
| 43 | DMRA | Damora Therapeutics INC | Stock-Other | 0.60% | +0.60% | NEW | |
| 44 | EPRX | Eupraxia Pharmaceuticals INC | Stock-Other | 0.59% | +0.46% | +429.67% | |
| 45 | ANRO | Alto Neuroscience INC | Stock-Other | 0.58% | +0.58% | NEW | |
| 46 | BBIO | Bridgebio Pharma INC | Stock-Healthcare | 0.58% | -0.81% | -53.13% | |
| 47 | CGEM | Cullinan Therapeutics INC | Stock-Other | 0.57% | -0.57% | -59.56% | |
| 48 | BLTE | Belite Bio INC - Adr | Stock-Other | 0.54% | +0.36% | +225.00% | |
| 49 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.52% | -2.10% | -48.08% | |
| 50 | VERA | Vera Therapeutics INC | Stock-Other | 0.52% | — | — |
Performance for Q3 2026
+21.4%
Performance Last 4 Quarters
+94.4%
Based on 77% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 105 | $1.9B | 78 | |
| 2025-12-31 | 95 | $1.8B | 96 | |
| 2025-09-30 | 96 | $1.1B | 100 | |
| 2025-06-30 | 91 | $732.2M | 0 | |
| 2025-03-31 | 98 | $1.0B | 100 | |
| 2024-12-31 | 85 | $746.0M | 0 | |
| 2024-09-30 | 86 | $732.8M | 0 | |
| 2024-06-30 | 98 | $867.5M | 0 | |
| 2024-03-31 | 95 | $807.8M | 0 | |
| 2023-12-31 | 82 | $547.5M | 0 | |
| 2023-09-30 | 81 | $355.5M | 0 | |
| 2023-06-30 | 70 | $286.3M | 0 | |
| 2023-03-31 | 74 | $303.0M | 0 | |
| 2022-12-31 | 63 | $255.0M | 0 | |
| 2022-09-30 | 64 | $358.3M | 0 | |
| 2022-06-30 | 54 | $237.2M | 0 | |
| 2022-03-31 | 59 | $625.0M | 0 | |
| 2021-12-31 | 55 | $275.4M | 0 | |
| 2021-09-30 | 73 | $396.0M | 0 | |
| 2021-06-30 | 69 | $279.3M | 100 | |
| 2021-03-31 | 72 | $294.5M | 95 | |
| 2020-12-31 | 62 | $188.7M | — |
Affinity Asset Advisors, LLC's most significant position changes for 2026-03-31: Sold out: Ss Spdr S&p Biotech ETF (XBI); New buy: Ss Spdr S&p 500 ETF Trust-us (SPY); Sold out: Ishares Biotechnology ETF (IBB); Sold out: Ventyx Biosciences INC (VTYXUSD); Sold out: Amgen INC (AMGN).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ERAS | Erasca INC | +3.6% | +37.18% | Add |
| 2 | 260 | Centessa Pharmaceuticals-adr | +2% | +133.12% | Add |
| 3 | ROIV | Roivant Sciences Ltd. | +1.9% | +64.71% | Add |
| 4 | XENE | Xenon Pharmaceuticals INC | +1.8% | +34.00% | Add |
| 5 | ANAB | Anaptysbio INC | +1.5% | +111.38% | Add |
| 6 | DNTH | Dianthus Therapeutics INC | +1.5% | +247.83% | Add |
| 7 | STRO | Sutro Biopharma INC | +0.9% | +42.91% | Add |
| 8 | ALKS | Alkermes plc | +0.9% | +35.00% | Add |
| 9 | COGT | Cogent Biosciences INC | +0.8% | +114.29% | Add |
| 10 | ASND | Ascendis Pharma A/S | +0.8% | +216.67% | Add |
| 11 | SYRE | Spyre Therapeutics INC | +0.7% | -10.71% | Trim |
| 12 | CATX | Perspective Therapeutics INC | +0.6% | +954.86% | Add |
| 13 | OVID | Ovid Therapeutics INC | +0.6% | +48.76% | Add |
| 14 | RVMD | Revolution Medicines INC | +0.6% | +100.00% | Add |
| 15 | MDGL | Madrigal Pharmaceuticals INC | +0.5% | +76.67% | Add |
| 16 | EPRX | Eupraxia Pharmaceuticals INC | +0.5% | +429.67% | Add |
| 17 | ARWR | Arrowhead Pharmaceuticals In | +0.4% | +185.71% | Add |
| 18 | COGT 1.625 11-15-31 | Cogent Biosciences INC | +0.4% | +600.00% | Add |
| 19 | BLTE | Belite Bio INC - Adr | +0.4% | +225.00% | Add |
| 20 | APGE | Apogee Therapeutics INC | +0.3% | +4.05% | Add |
| 21 | 430 | Terns Pharmaceuticals INC | +0.3% | +2.30% | Add |
| 22 | ACLXGBX | Arcellx INC | +0.2% | -30.73% | Trim |
| 23 | ✓ | Establishment Labs Hldgs INC | -0.5% | -50.00% | Trim |
| 24 | CGEM | Cullinan Therapeutics INC | -0.6% | -59.56% | Trim |
| 25 | TSHA | Taysha Gene Therapies INC | -0.8% | -69.70% | Trim |
| 26 | BBIO | Bridgebio Pharma INC | -0.8% | -53.13% | Trim |
| 27 | QURE | uniQure N.V. | -0.9% | -64.71% | Trim |
| 28 | ABVX | Abivax Sa-adr | -1.6% | -19.80% | Trim |
| 29 | WVE | Wave Life Sciences Ltd. | -2.1% | -48.08% | Trim |
| 30 | XBI | Ss Spdr S&p Biotech ETF | — | EXIT | Sold out |
| 31 | SPY | Ss Spdr S&p 500 ETF Trust-us | — | NEW | New buy |
| 32 | IBB | Ishares Biotechnology ETF | — | EXIT | Sold out |
| 33 | VTYXUSD | Ventyx Biosciences INC | — | EXIT | Sold out |
| 34 | AMGN | Amgen INC | — | EXIT | Sold out |
| 35 | MRNA | Moderna INC | — | NEW | New buy |
| 36 | XLV | Ss Health Care Select Sector | — | EXIT | Sold out |
| 37 | ELVN | Enliven Therapeutics INC | — | NEW | New buy |
| 38 | BMY | Bristol-myers Squibb Co | — | NEW | New buy |
| 39 | ✓ | Helix Acquisition CORP Iii | — | NEW | New buy |
| 40 | DMRA | Damora Therapeutics INC | — | NEW | New buy |
| 41 | ANRO | Alto Neuroscience INC | — | NEW | New buy |
| 42 | TVTX 2.25 03-01-29 | Travere Therapeutics INC | — | EXIT | Sold out |
| 43 | TYRA | Tyra Biosciences INC | — | NEW | New buy |
| 44 | IBRX | Immunitybio INC | — | NEW | New buy |
| 45 | TNGX | Tango Therapeutics INC | — | EXIT | Sold out |
| 46 | KRRO | Korro Bio INC | — | NEW | New buy |
| 47 | RCUS | Arcus Biosciences INC | — | EXIT | Sold out |
| 48 | CRSP | CRISPR Therapeutics AG | — | NEW | New buy |
| 49 | SGP | Spyglass Pharma INC | — | NEW | New buy |
| 50 | NVO | Novo-nordisk A/s-spons Adr | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-14 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-13 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-13 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-13 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-14 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-13 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-13 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-14 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-13 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-21 | Amendment | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-13 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-12 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-13 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-11 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-12 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-13 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-14 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-12 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001483532
Total reported value
$1.9B
60 stks
2020-09-30
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001047142
Total reported value
$1.9B
262 stks
2026-06-30
AUM within 0.1% of this institution
CIK 0001163902
Total reported value
$1.9B
395 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001615982
Total reported value
$2.7B
33 stks
2026-03-31
2 of the top 5 holdings overlap, including Apogee Therapeutics INC
CIK 0000014745
Total reported value
$400.4M
1,021 stks
2026-03-31
1 of the top 5 holdings overlap, including Ss Spdr S&p 500 ETF Trust-us
CIK 0000018349
Total reported value
$8.7B
1,549 stks
2025-09-30
Stale — no recent filing
1 of the top 5 holdings overlap, including Ss Spdr S&p 500 ETF Trust-us